Beyond
the headlines.

1. STUDY 01Findings added Sep 16, 2026

   Semaglutide

   TL;DR

   Semaglutide subgroup showed weight loss during antipsychotic treatment

   In randomized trials of adjunctive GLP-1 receptor agonists for antipsychotic-treated patients, the semaglutide subgroup showed reductions in body weight and BMI.

   The comparator underlying the semaglutide subgroup estimates is not available in this summary, so their numerical magnitudes are not presented. Between-agent subgroup differences were reported.

   Study details & original results

   Moubarak, Elsayed S et al.. Adjunctive GLP-1 receptor agonists for cardiometabolic risk in antipsychotic-treated patients: A GRADE-assessed meta-analysis of randomized trials.. Journal of psychopharmacology (Oxford, England). 2026.

   Body-weight reduction with semaglutide in a GLP-1 RA type subgroup analysis of randomized trials involving antipsychotic-treated patients; between-agent subgroup differences for weight and BMI were significant at p<0.05.

   MD -11.06 kg

   BMI reduction with semaglutide in a GLP-1 RA type subgroup analysis of randomized trials involving antipsychotic-treated patients; between-agent subgroup differences for weight and BMI were significant at p<0.05.

   MD -3.60 kg/m²

   Citation in Semaglutide

   One key learningRead original study in a new tab
2. STUDY 02Findings added Sep 13, 2026

   SemaglutideTirzepatide

   TL;DR

   Tirzepatide produced more weight loss than semaglutide

   -20.2% vs -13.7%

   In an open-label randomized active-controlled trial of adults with overweight or obesity, mean body-weight change at 72 weeks was -20.2% with tirzepatide versus -13.7% with semaglutide.

   Retrospective cohorts also favored tirzepatide, but effects were smaller and heterogeneous, and several cohorts had serious confounding-related bias.

   -20.2% vs -13.7%

   Randomized trial weight loss favored tirzepatide over semaglutide

   In an open-label randomized active-controlled trial, mean weight change at 72 weeks was -20.2% with tirzepatide and -13.7% with semaglutide.

   Real-world cohorts also favored tirzepatide by approximately 2.3-4.4 percentage points, but heterogeneity prevented pooling and four cohorts had serious risk of bias, principally from unadjusted confounding.

   Study details & original results

   Mohamed Abdalla, Samih Abdelmutalab et al.. Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic Review.. Cureus. 2026.

   Mean body-weight change at 72 weeks with tirzepatide versus semaglutide in a phase 3b open-label, randomized, active-controlled trial of adults with overweight or obesity.

   -20.2% vs -13.7%

   Range of adjusted between-group weight-loss differences across retrospective real-world cohorts; the advantage was smaller than in the trial and most pronounced at stringent weight-reduction thresholds. Substantial heterogeneity precluded meta-analysis, and four cohorts had serious risk of bias, principally from unadjusted confounding.

   approximately 2.3-4.4 percentage points favoring tirzepatide

   Citation in Semaglutide

   Mean weight change at 72 weeks with tirzepatide versus semaglutide in the included phase 3b open-label randomized active-controlled trial.

   -20.2% vs -13.7%

   Adjusted weight-reduction advantage favoring tirzepatide over semaglutide in real-world cohorts; substantial heterogeneity precluded meta-analysis, and four cohorts were judged at serious risk of bias, principally because of unadjusted confounding.

   Approximately 2.3-4.4 percentage points

   Citation in Tirzepatide

   2 key learningsRead original study in a new tab
3. STUDY 03Findings added Sep 12, 2026

   Tirzepatide

   TL;DR

   Spontaneous suicide-related reports cannot establish clinical risk

   47 tirzepatide cases (37 liraglutide; 141 semaglutide)

   There were 47 tirzepatide suicide or self-injury reports among 42,941 eligible European pharmacovigilance reports; semaglutide and liraglutide had higher reporting disproportionality than tirzepatide.

   These were spontaneous reports from 2021 through 2025, not incidence data. Reporting biases apply, and the findings do not establish causality.

   Study details & original results

   Scavone, Cristina et al.. Reporting patterns of suicide- and self-injury-related events involving liraglutide, semaglutide, and tirzepatide: data from the European pharmacovigilance database.. Frontiers in pharmacology. 2026.

   Reported suicide/self-injury cases among 42,941 eligible EudraVigilance reports from 2021 through 2025. These are spontaneous-report counts, not incidence estimates, and do not establish causality.

   47 tirzepatide cases (37 liraglutide; 141 semaglutide)

   Reporting frequency of suicide/self-injury events with semaglutide versus tirzepatide. This is a spontaneous-report disproportionality comparison, not an estimate of clinical incidence or causal risk, and is subject to pharmacovigilance-reporting limitations.

   ROR 2.69
   95% CI: 1.91-3.83

   Reporting frequency of suicide/self-injury events with liraglutide versus tirzepatide. This is a spontaneous-report disproportionality comparison, not an estimate of clinical incidence or causal risk, and is subject to pharmacovigilance-reporting limitations.

   ROR 2.54
   95% CI: 1.60-4.01

   Citation in Tirzepatide

   One key learningRead original study in a new tab
4. STUDY 04Findings added Sep 11, 2026

   SemaglutideTirzepatide

   TL;DR

   Semaglutide was followed by weight loss after bariatric surgery

   9.02% total weight loss

   Among adults starting an incretin receptor agonist at least one year after metabolic bariatric surgery, semaglutide was associated with 9.02% total weight loss at 12 months.

   Heterogeneity across studies was substantial. At 6 months, tirzepatide produced greater total weight loss than semaglutide, but that pooled comparison was also heterogeneous.

   4.23% greater mean total weight loss

   Weight-loss meta-analysis favored tirzepatide over semaglutide after surgery

   At 6 months, the meta-analysis favored tirzepatide over semaglutide by 4.23% in mean total weight loss.

   The meta-analysis included adults treated at least one year after metabolic bariatric surgery. Substantial heterogeneity across studies requires cautious interpretation.

   Study details & original results

   Santos-Pereira, Mariana et al.. Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery - a systematic review and meta-analysis.. Frontiers in endocrinology. 2026.

   Total weight loss at 12 months with semaglutide in adults treated with an incretin receptor agonist at least one year after metabolic bariatric surgery; substantial heterogeneity across studies requires cautious interpretation.

   9.02% total weight loss

   Mean difference in total weight loss at 6 months for tirzepatide versus semaglutide after metabolic bariatric surgery; substantial heterogeneity across studies requires cautious interpretation.

   MD 4.23% favoring tirzepatide

   Citation in Semaglutide

   At 6 months, tirzepatide was favored over semaglutide for total weight loss among adults treated at least one year after metabolic bariatric surgery; the authors cautioned that substantial heterogeneity across studies requires cautious interpretation.

   4.23% greater mean total weight loss

   Citation in Tirzepatide

   2 key learningsRead original study in a new tab

Dates show when findings were added here, not when papers were published. Study populations and comparisons differ.